Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial

NCT07830511 is registered in ClinicalTrials.gov with Robert Förster as lead sponsor.

NCT NCT07830511
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07830511 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RIsk aDapted Stereotactic Radiotherapy vs. standarD of Care Radiotherapy in Patients With Prostate Cancer in the Adjuvant or saLvage sEtting With or Without Lymph Node Irradiation (RIDDLELN) - A Phase III Trial
Lead sponsor
Robert Förster
Phase
Phase 3
Overall status
Not yet recruiting
Start date
September 1, 2026
Completion date
September 1, 2034
Enrollment
206 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer, prostate cancer (post prostatectomy), sbrt